Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households

BACKGROUND: Immunosuppressive agents used in the treatment of inflammatory bowel diseases (IBDs) could potentially increase the risk of coronavirus disease 2019 (COVID-19). We aimed to compare COVID-19 frequency in patients with IBD with their households and identify the related risk factors. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Anushiravani, Amir, Saberzadeh-Ardestani, Bahar, Vahedi, Homayoon, Fakheri, Hafez, Mansour-Ghanaei, Fariborz, Maleki, Iraj, Nasseri-Moghaddam, Siavosh, Vosoghinia, Hasan, Ghadir, Mohammad Reza, Hormati, Ahmad, Kasaeian, Amir, Radmard, Amir Reza, Khosravi, Bardia, Malekzadeh, Masoud, Alatab, Sudabeh, Sadeghi, Anahita, Aminisani, Nayyereh, Poustchi, Hossein, Sima, Ali Reza, Malekzadeh, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Association of Gastroerterology and Hepatology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489316/
https://www.ncbi.nlm.nih.gov/pubmed/36619152
http://dx.doi.org/10.34172/mejdd.2022.271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489316/
https://www.ncbi.nlm.nih.gov/pubmed/36619152
http://dx.doi.org/10.34172/mejdd.2022.271

Ejemplares similares